The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

13 Aug 2010 11:22

RNS Number : 0504R
Credit Suisse Securities (Eur) Ltd
13 August 2010
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Credit Suisse Securities (Europe) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ARK THERAPEUTICS GROUP PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

ARK THERAPEUTICS GROUP PLC

(d) Date dealing undertaken:

12-August-2010

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary shares

Purchase

 

60,000

0.0503 (GBP)

0.0469 (GBP)

Ordinary shares

Sales

 

60,000

0.0503 (GBP)

0.0469 (GBP)

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

Date of disclosure:

13-August-2010

Contact name:

Vas Eliades/ Liane Agostini

Telephone number:

0207 888 6659

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBGGDIBDBBGGX
Date   Source Headline
6th Jun 20122:41 pmRNSBlocklisting Interim Review
18th May 201212:02 pmRNSHolding(s) in Company
18th May 201212:01 pmRNSDirector Dealings
18th May 201211:57 amRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
16th May 20127:00 amRNSCompletion of Phase 1 Study
2nd May 20127:00 amRNSGrant and Patent Update
25th Apr 20127:00 amRNSRegulatory Approval of Manufacturing Suite
17th Apr 20122:36 pmRNSDirector/PDMR Shareholding
10th Apr 20127:00 amRNSNew Board Appointment
2nd Apr 20123:25 pmRNSAnnual Information Update
26th Mar 20127:00 amRNSChange of Broker Name
15th Mar 20124:09 pmRNSDirector/PDMR Shareholding
13th Mar 20124:16 pmRNSBoard Changes
12th Mar 20127:00 amRNSFinal Results
23rd Feb 20124:29 pmRNSHolding(s) in Company
9th Feb 201211:10 amRNSNotice of Results
8th Feb 20127:00 amRNSUS patent for Neuropilin-1 receptor
4th Jan 20127:00 amRNSManufacturing Update
7th Dec 201111:48 amRNSDirector/PDMR Shareholding
5th Dec 20112:35 pmRNSBlocklisting Interim Review
9th Nov 20117:00 amRNSInterim Management Statement
3rd Nov 20117:00 amRNSManufacturing agreement
16th Sep 20114:41 pmRNSSecond Price Monitoring Extn
16th Sep 20114:35 pmRNSPrice Monitoring Extension
12th Sep 20117:00 amRNSRe Agreement
24th Aug 20115:29 pmRNSHalf Yearly Report on National Storage Mechanism
24th Aug 20117:00 amRNSHalf Yearly Report - Part 2
24th Aug 20117:00 amRNSHalf Yearly Report - Part 1
1st Aug 20114:31 pmRNSHolding(s) in Company
29th Jul 20114:40 pmRNSSecond Price Monitoring Extn
29th Jul 20114:35 pmRNSPrice Monitoring Extension
25th Jul 20114:40 pmRNSSecond Price Monitoring Extn
25th Jul 20114:35 pmRNSPrice Monitoring Extension
18th Jul 20113:10 pmRNSHolding(s) in Company
14th Jul 20117:00 amRNSWins ?5.3 million EU Framework Programme 7 Grant
6th Jul 20117:00 amRNSArk receives Finnish Grants
4th Jul 20117:00 amRNSGrant of US patents and milestone payments
13th Jun 20114:40 pmRNSSecond Price Monitoring Extn
13th Jun 20114:35 pmRNSPrice Monitoring Extension
3rd Jun 201111:57 amRNSBlocklisting Interim Review
17th May 20117:00 amRNSInterim Management Statement
9th May 20113:28 pmRNSAGM Results
31st Mar 20111:43 pmRNSAnnual Information Update
30th Mar 20111:08 pmRNSDirector/PDMR Shareholding
24th Mar 20113:40 pmRNSAnnual Financial Report
9th Mar 20117:00 amRNSFinal Results
3rd Mar 20117:00 amRNSAppointment of CFO
2nd Mar 20117:00 amRNSDisposal
28th Feb 201111:49 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.